Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital

References

• Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012;125(1 Suppl):S3-13
   PubMed Web of Science ®Google Scholar
• Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34
   PubMed Web of Science ®Google Scholar
• Cornely OA, Böhme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009;94:113-22
   PubMed Web of Science ®Google Scholar
• Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008;6:122-74
   PubMedGoogle Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60
   PubMed Web of Science ®Google Scholar
• Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008;65:2237-43
   PubMed Web of Science ®Google Scholar
• Stam WB, O'Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008;81:467-74
   PubMed Web of Science ®Google Scholar
• O'Sullivan AK, Pandya A, Papadopoulos G, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health 2009;12:666-73
   PubMed Web of Science ®Google Scholar
• Greiner RA, Meier Y, Papadopoulos G, et al. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology 2010;78:172-80
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. Support Cancer Care 2011;19:1807-13
   PubMed Web of Science ®Google Scholar
• Michallet M, Gangneux JP, Lafuma A, et al. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. J Med Econ 2011;14:28-35
   PubMedGoogle Scholar
• Tahami Monfared AA, O'Sullivan AK, Rotstein C, et al. Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol 2012;23:59-64
   PubMed Web of Science ®Google Scholar
• Lundberg J1, Höglund M, Björkholm M, et al. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden. Clin Drug Investig 2014;34:483-9
   PubMed Web of Science ®Google Scholar
• Hsu LY, Lee DG, Yeh SP, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Clin Microbiol Infect 2015;21:594.e7-e11
   PubMedGoogle Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER Cancer Statistics Review 1975–2003. Age-adjusted SEER incidence and US death rates and 5-year relative survival rates. 2006. http://seer.cancer.gov/csr/1975_2003/results_single/sect_01_table.04_2pgs.pdf. Accessed April 21, 2015
   Google Scholar
• Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006;106:1099-109
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al, eds.Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
   Google Scholar
• Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health 2004;7:397-401
   PubMed Web of Science ®Google Scholar
• HKSAR Go. Hong Kong Life Tables 1971–2012. Census and Statistics Department, 2012
   Google Scholar
• Edejer TT-T, World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003
   Google Scholar
• Chan TS, Hwang YY, Gill H, et al. Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital. Intern Med J 2013;43:541-6
   PubMed Web of Science ®Google Scholar
• Edejer TT-T, World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003
   Google Scholar
• National income, Census and Statistics Department, Hong Kong Special Administrative Region. http://www.censtatd.gov.hk/hkstat/sub/sp250.jsp?tableID=030&ID=0&productType=8. Accessed March 27, 2015
   Google Scholar
• SEER Cancer Statistics Review (CSR) 1975–2012. National Cancer Institute, http://seer.cancer.gov/csr/1975_2012/. Accessed August 28, 2015
   Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65
   PubMed Web of Science ®Google Scholar